DK0458937T3 - Varianter af PAI-2 - Google Patents

Varianter af PAI-2

Info

Publication number
DK0458937T3
DK0458937T3 DK91901253.4T DK91901253T DK0458937T3 DK 0458937 T3 DK0458937 T3 DK 0458937T3 DK 91901253 T DK91901253 T DK 91901253T DK 0458937 T3 DK0458937 T3 DK 0458937T3
Authority
DK
Denmark
Prior art keywords
variants
pai
pct
sec
compositions
Prior art date
Application number
DK91901253.4T
Other languages
English (en)
Inventor
Neil Howard Goss
Michael Andrew Richardson
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of DK0458937T3 publication Critical patent/DK0458937T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91901253.4T 1989-12-20 1990-12-20 Varianter af PAI-2 DK0458937T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ792489 1989-12-20

Publications (1)

Publication Number Publication Date
DK0458937T3 true DK0458937T3 (da) 1998-02-23

Family

ID=3774424

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91901253.4T DK0458937T3 (da) 1989-12-20 1990-12-20 Varianter af PAI-2

Country Status (10)

Country Link
US (1) US5444153A (da)
EP (1) EP0458937B1 (da)
JP (1) JP2567536B2 (da)
AT (1) ATE156859T1 (da)
AU (1) AU625018B2 (da)
DE (1) DE69031271T2 (da)
DK (1) DK0458937T3 (da)
ES (1) ES2106772T3 (da)
GR (1) GR3025330T3 (da)
WO (1) WO1991009124A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
DE4214999C2 (de) * 1992-05-06 1994-07-14 Behringwerke Ag Reinigung von Plasminogen-Aktivator-Inhibitor 2 durch Immunaffinitätschromatographie
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
CN1196701C (zh) 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
KR20010042402A (ko) 1998-04-01 2001-05-25 로잘란드 앤 칼도르 피부 상처의 치료를 위한 프로테아제 억제제의 용도
AUPP508798A0 (en) 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
US8062637B2 (en) * 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6562572B1 (en) * 2000-09-27 2003-05-13 Mayo Foundation For Medical Education And Research Methods for amplifying nucleic acid sequences
WO2009068926A1 (en) * 2007-11-30 2009-06-04 University Of Debrecen Use of urokinase type plasminogen activator inhibitors for the treatment of corneal disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
DE3587711T2 (de) * 1984-08-13 1994-04-28 Biotech Australia Pty Ltd Minaktivin.
IL81879A (en) * 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
AU608752B2 (en) * 1986-03-13 1991-04-18 Australian National University, The Minactivin produced by recombinant dna technology
DE3722673A1 (de) * 1987-04-18 1989-01-19 Behringwerke Ag Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
EP0446315B1 (en) * 1989-09-05 1997-06-11 Biotechnology Australia Pty. Ltd. Process for the preparation of pai-2

Also Published As

Publication number Publication date
AU6967191A (en) 1991-07-18
US5444153A (en) 1995-08-22
AU625018B2 (en) 1992-06-25
EP0458937A4 (en) 1992-04-01
DE69031271D1 (de) 1997-09-18
ES2106772T3 (es) 1997-11-16
DE69031271T2 (de) 1998-02-26
WO1991009124A1 (en) 1991-06-27
EP0458937B1 (en) 1997-08-13
JPH04503761A (ja) 1992-07-09
ATE156859T1 (de) 1997-08-15
JP2567536B2 (ja) 1996-12-25
EP0458937A1 (en) 1991-12-04
GR3025330T3 (en) 1998-02-27

Similar Documents

Publication Publication Date Title
DK0458937T3 (da) Varianter af PAI-2
Tokunaga et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha,-V beta, and-V gamma and their complete amino acid sequences.
Tsujinaka et al. Synthesis of a new cell penetrating calpain inhibitor (calpeptin)
Vissers et al. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils.
DE69027024D1 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
CA2058935A1 (en) Pharmaceutical compositions and method for treatment using alzheimer's amyloid peptides
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
Neves-Ferreira et al. Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum
Glover et al. Synthetic peptide inhibitors of complement serine proteases—I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D
Samuels et al. A cuticle-degrading proteinase from the moulting fluid of the tobacco hornworm, Manduca sexta
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
Bradford et al. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
de Agostini et al. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
Lindsay et al. Isolation and characterization of ovochymase, a chymotrypsin-like protease released during Xenopus laevis egg activation
Elion et al. Proteolytic derivatives of thrombin
JPH02147954A (ja) ヒトの血清または血漿におけるオステオカルシンの決定法
Abrahamson et al. Modification of cystatin C activity by bacterial proteinases and neutrophil elastase in periodontitis.
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Norman Effect of urea and methylamine on plasmin.
Heins et al. Kinetic investigation of the hydrolysis of aminoacyl p-nitroanilides by dipeptidyl peptidase IV from human and pig kidney
Samama et al. Crystallization and preliminary crystallographic data for bovine antithrombin III
Mende et al. Three recombinant serine proteinase inhibitors expressed from the coding region of the thrombin inhibitor dipetalogastin